Idiopathic Pulmonary Fibrosis — Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
Citation(s)
Dose Ranging Study of Oral Epigallocatechin-3-gallate (EGCG) Given Daily for 12 Weeks to Patients With Idiopathic Pulmonary Fibrosis (IPF) Evaluating Safety, PK Interactions With Standard of Care Drugs, and Biomarkers of Drug Effect